Hanrahan et al evaluated survival for women with T1a,bN0M0 breast carcinoma. This can help identify a woman who may benefit from more aggressive management. The authors are from University of Texas M.D. Anderson Cancer Center in Houston and the Insitut Gustave Roussy in Villejuif, France.
Patient selection: T1a or T1b (from 1.01 to 10 mm in diameter), N0 and M0
Parameters:
(1) histologic grade
(2) estrogen receptor (ER) status
(3) progesterone receptor (PR) status
(4) number of lymph nodes sampled
(5) diameter of the tumor in mm
(6) age of the patient in years
Parameter |
Finding |
Points |
histologic grade |
Grade I (well-differentiated) |
0 |
|
Grade II |
28 |
|
Grade III (poorly differentiated) |
56 |
ER status |
negative |
40 |
|
positive |
0 |
PR status |
negative |
13 |
|
positive |
0 |
lymph nodes sampled |
0 |
53 |
|
1 to 3 |
8.8 |
|
4 to 9 |
2.5 |
|
>= 10 |
0 |
points for age 20 to 60 =
= (0.03920 * ((age)^2)) - (5.335 * (age)) + 178.9
points for age 60 to 110 =
= (0.02084 * ((age)^2)) - (1.471 * (age)) + 11.44
points for size =
= MAX(0,(2.5 * (diameter in mm)) - 2.5)
total score =
= SUM(points for all 6 parameters)
Interpretation:
• minimum score: 0
• maximum score: around 260
• The higher the score the worse the survival.
Total Score |
Probability of 10 Year Disease Specific Survival |
< 81 |
> 95% |
81 to 240 |
(-0.001858 * ((points)^2)) + (0.2887 * (points)) + 83.42 |
> 240 |
< 45% |
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
ICD-10: ,